ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

NICOLE JOSEPH MD

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,845Medicare Part D Prescriptions Filled, Including Refills

Rank: 115 out of 663

$262K Total Retail Price of All Prescriptions

Rank: 280 out of 663

367 Patients Receiving at Least One Drug in Part D
47%Patients 65 Years and Older
96% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Colorado
Lower avg

Schedule Two
Controlled Substances

23% of this provider’s 367 patients filled at least one prescription for a schedule two drug, compared to an average of 8%.

Schedule Three
Controlled Substances

13% of this provider’s 367 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

3% of this provider’s 3,834 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$33 was the average price of a prescription from this provider, compared to $56 among peers.

Prescriptions per Patient

21 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Colorado
LISINOPRIL 508 325 1 2
AMLODIPINE BESYLATE 281 181 2 5
HYDROCODONE-ACETAMINOPHEN 248 127 S3 3 6
RANITIDINE HCL 247 130 4 31
SIMVASTATIN 241 93 5 1
OMEPRAZOLE 226 92 6 4
HYDROCHLOROTHIAZIDE 224 116 7 12
LEVOTHYROXINE SODIUM 213 111 8 3
OXYCODONE-ACETAMINOPHEN 207 55 S2 9 26
METFORMIN HCL 200 89 10 9
PROAIR HFA 189 70 11 33
FUROSEMIDE 172 110 12 7
ATENOLOL 165 92 13 10
COMBIVENT 143 79 14 125
GABAPENTIN 142 66 15 20
CRESTOR 132 92 16 37
TRAMADOL HCL 114 61 17 17
CYCLOBENZAPRINE HCL 110 30 R 18 71
METOPROLOL TARTRATE 87 71 19 11
LOVASTATIN 86 44 20 30
FELODIPINE ER 85 66 21 114
FLUTICASONE PROPIONATE 85 25 21 27
LOSARTAN POTASSIUM 84 55 23 14
MORPHINE SULFATE ER 83 12 S2 24 51
FLUOXETINE HCL 82 0 25 32
LISINOPRIL-HYDROCHLOROTHIAZIDE 78 28 26 22
NEXIUM 78 21 26 43
WARFARIN SODIUM 78 47 26 8
AMITRIPTYLINE HCL 75 44 R 29 95
IBUPROFEN 74 24 30 89
MONOJECT INSULIN SYRINGE 70 45 31 201
ATORVASTATIN CALCIUM 69 35 32 13
TAMSULOSIN HCL 65 54 33 24
TRAZODONE HCL 64 26 34 34
GEMFIBROZIL 62 25 35 109
DICLOFENAC SODIUM 62 45 35 112
HYDRALAZINE HCL 62 38 35 101
SERTRALINE HCL 56 20 38 35
NOVOLIN N 54 29 39 44
ALLOPURINOL 53 32 40 28
OXYCODONE HCL 52 14 S2 41 41
CITALOPRAM HBR 50 19 42 18
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.